Today: 23 May 2026
Browse Category

NYSE:LLY 1 December 2025 - 12 December 2025

Eli Lilly stock LLY after hours on Dec. 12, 2025: Mounjaro pediatric EU nod, FDA orforglipron fast-track scrutiny, and what to watch next

Eli Lilly stock LLY after hours on Dec. 12, 2025: Mounjaro pediatric EU nod, FDA orforglipron fast-track scrutiny, and what to watch next

Eli Lilly shares closed at $1,027.51, up 1.8% Friday, and traded near $1,028–$1,029 after hours following a European regulatory panel’s recommendation to expand Mounjaro use to children 10 and older with type 2 diabetes. Volume was about 3.2 million shares. The stock remains 7.6% below its 52-week high set in late November.
12 December 2025
··
Eli Lilly Stock (NYSE: LLY) in Focus: Retatrutide’s Near-30% Weight-Loss Data, FDA Fast-Track Questions for Orforglipron, and Fresh Analyst Forecasts (Dec. 12, 2025)

Eli Lilly Stock (NYSE: LLY) in Focus: Retatrutide’s Near-30% Weight-Loss Data, FDA Fast-Track Questions for Orforglipron, and Fresh Analyst Forecasts (Dec. 12, 2025)

Eli Lilly shares traded near $1,009 Friday after its obesity drug retatrutide showed 28.7% average weight loss in a Phase 3 trial, though with notable discontinuation rates. Reuters reported FDA leaders pushed to speed review of Lilly’s oral GLP-1 drug orforglipron, raising internal concerns. The company is building a $6 billion Alabama plant to boost manufacturing. Analyst price targets remain supportive but vary widely.
12 December 2025
··
Eli Lilly (LLY) Stock After Hours on December 11, 2025: Retatrutide Breakthrough, $6B Plant — and What to Watch Before Friday’s Open

Eli Lilly (LLY) Stock After Hours on December 11, 2025: Retatrutide Breakthrough, $6B Plant — and What to Watch Before Friday’s Open

Eli Lilly shares closed Thursday near $1,006 after new Phase 3 data showed its obesity drug retatrutide cut body weight by up to 28.7% in patients with knee osteoarthritis. The company announced a $6 billion plant in Alabama and reported Q3 revenue up 54% to $17.6 billion. Mounjaro will be covered by China’s national health insurance from January.
11 December 2025
···
Eli Lilly (LLY) Stock After the $1 Trillion Milestone: Latest News, Analyst Targets and 2026 Outlook

Eli Lilly (LLY) Stock After the $1 Trillion Milestone: Latest News, Analyst Targets and 2026 Outlook

Eli Lilly became the first pharmaceutical company to surpass a $1 trillion market value on November 21, 2025, driven by strong demand for its obesity and diabetes drugs. By December 11, shares traded near $993, with a market cap of about $890 billion, down from the peak. The company’s stock is up over 550% in five years, far outpacing the S&P 500. Investors are now focused on valuation rather than growth.
11 December 2025
··
Best Stocks to Buy Now in the U.S. Stock Market (December 11, 2025)

Best Stocks to Buy Now in the U.S. Stock Market (December 11, 2025)

The Federal Reserve cut rates by 25 basis points, but markets remain volatile as concerns grow over a potential AI spending bubble. Oracle shares fell more than 11% after warning of sharply higher AI costs, dragging down Nvidia, Microsoft, and Amazon. Major banks expect further Fed easing in 2026. Analysts highlight Nvidia, Microsoft, Alphabet, Vertiv, Eli Lilly, General Motors, Goldman Sachs, and Campbell’s as stocks to watch.
11 December 2025
········
Eli Lilly (LLY) Stock Near $1 Trillion: Zepbound Price Cuts, New $6B Plant and 2026 Dividend Hike – Is It Still a Buy?

Eli Lilly (LLY) Stock Near $1 Trillion: Zepbound Price Cuts, New $6B Plant and 2026 Dividend Hike – Is It Still a Buy?

Eli Lilly shares traded near $980 midday Monday, after briefly surpassing $1,050 and becoming the first healthcare firm valued above $1 trillion. Q3 revenue rose 54% to $17.6 billion, fueled by Zepbound and Mounjaro sales topping $10 billion. The company announced a $6 billion Alabama plant for its oral weight-loss drug and completed its Adverum Biotechnologies acquisition. LLY trades at about 49 times trailing earnings, far above big-pharma averages.
10 December 2025
··
Abivax (ABVX) Stock Jumps on Eli Lilly Takeover Rumors: Latest News, Outlook and Forecasts – December 10, 2025

Abivax (ABVX) Stock Jumps on Eli Lilly Takeover Rumors: Latest News, Outlook and Forecasts – December 10, 2025

Abivax shares surged as much as 20% on December 10, 2025, in Paris trading amid market rumors of a possible takeover bid by Eli Lilly. The stock hit a 52-week high near €126.60, with market value reaching about €9.7 billion. Abivax declined to comment, and no formal offer has been announced. U.S.-listed ADRs also jumped over 11% in pre-market trading.
10 December 2025
····
Eli Lilly’s $6 Billion Huntsville Plant: 450 High‑Paying Jobs, GLP‑1 Drug Boom and Alabama’s Biggest Industrial Bet

Eli Lilly’s $6 Billion Huntsville Plant: 450 High‑Paying Jobs, GLP‑1 Drug Boom and Alabama’s Biggest Industrial Bet

Eli Lilly will invest over $6 billion to build a pharmaceutical manufacturing campus in Huntsville, Alabama, creating 450 permanent and 3,000 construction jobs. The 260-acre facility will produce active ingredients for small-molecule and peptide medicines, including the oral GLP-1 obesity drug orforglipron. Construction is set to begin in 2026 and finish by 2032. State officials call it Alabama’s largest-ever private industrial investment.
10 December 2025
·
Eli Lilly Stock After Hours on December 9, 2025: 9‑Day Slide, $6B Alabama Bet and What to Watch Before the December 10 Open

Eli Lilly Stock After Hours on December 9, 2025: 9‑Day Slide, $6B Alabama Bet and What to Watch Before the December 10 Open

Eli Lilly shares closed down 1.5% at $982.22 on Tuesday, marking a ninth straight daily decline despite announcing a $6 billion manufacturing facility in Huntsville, Alabama. The stock traded flat after hours but rebounded over 3% in early pre-market trading Wednesday, last seen near $1,013. Volume Tuesday reached about 2.5 million shares. The new plant will focus on GLP-1 and small-molecule drug production.
10 December 2025
··
Eli Lilly Stock (LLY) on December 9, 2025: Price, Alabama Megaplant, Jaypirca Breakthrough and 2026–2030 Forecasts

Eli Lilly Stock (LLY) on December 9, 2025: Price, Alabama Megaplant, Jaypirca Breakthrough and 2026–2030 Forecasts

Eli Lilly shares traded near $980 Tuesday, down 1.6% but up 57% from their 52-week low, with a market cap around $880 billion after briefly topping $1 trillion in November. The company announced a $6 billion manufacturing facility in Alabama, reported strong Q3 earnings, raised guidance, and posted an 80% risk reduction in a key leukemia trial. Lilly also closed its Adverum acquisition and raised its dividend.
9 December 2025
·
Eli Lilly (LLY) Stock on December 9, 2025: Jaypirca Breakthrough, Adverum Deal and Zepbound Price Cuts Reframe the Outlook

Eli Lilly (LLY) Stock on December 9, 2025: Jaypirca Breakthrough, Adverum Deal and Zepbound Price Cuts Reframe the Outlook

Eli Lilly shares traded near $997 early Monday, about 10% below last month’s record high. The company released Phase 3 data showing Jaypirca cut disease progression risk by 80% in untreated CLL/SLL, closed its Adverum Biotechnologies acquisition, and raised its quarterly dividend 15% to $1.73. Lilly also cut Zepbound prices and reported Q3 revenue up 54% to $17.6 billion.
9 December 2025
Eli Lilly (LLY) Stock After Hours on December 8, 2025: China Mounjaro Win, Dividend Hike and What to Watch Before Tuesday’s Open

Eli Lilly (LLY) Stock After Hours on December 8, 2025: China Mounjaro Win, Dividend Hike and What to Watch Before Tuesday’s Open

Eli Lilly shares closed at $998 on December 8, down 1.3%, marking a seventh straight decline and leaving the stock about 10% below its recent high. The company reported a 15% dividend increase, secured Chinese reimbursement for Mounjaro, and saw Nobel laureate Carolyn Bertozzi return to its board. Competition and price cuts in weight-loss drugs weighed on the stock.
9 December 2025
······
Eli Lilly (LLY) Stock on December 8, 2025: China Insurance Win, Trillion‑Dollar Status and What Comes Next for Investors

Eli Lilly (LLY) Stock on December 8, 2025: China Insurance Win, Trillion‑Dollar Status and What Comes Next for Investors

Eli Lilly shares traded near $1,010 Monday, keeping its valuation close to $1 trillion after surging demand for GLP-1 drugs. China will add Mounjaro to its state insurance list from January 2026, opening a large market but at lower prices. U.S. price cuts and political pressure weigh on margins. Q3 revenue jumped 54% to $17.6 billion, with analysts citing high growth expectations and a premium valuation as risks.
8 December 2025
·
Eli Lilly (LLY) Stock: Key Catalysts to Watch Before the Market Opens on December 8, 2025

Eli Lilly (LLY) Stock: Key Catalysts to Watch Before the Market Opens on December 8, 2025

Eli Lilly shares closed Friday at $1,010.31, down 0.41%, before edging higher after hours. The stock sits about 9% below its late-November record high. Over the weekend, China added Lilly’s Alzheimer’s drug Kisunla to a new insurance list for high-priced therapies, offering improved market access with smaller price cuts than usual. Investors await Monday’s session for reaction.
7 December 2025
··
Eli Lilly (LLY) Stock on 6 December 2025: Zepbound Price Cuts, $1 Trillion Milestone and 2026 Forecasts

Eli Lilly (LLY) Stock on 6 December 2025: Zepbound Price Cuts, $1 Trillion Milestone and 2026 Forecasts

Eli Lilly shares traded near $1,010 on December 6, 2025, with a market value just under $1 trillion after a brief pullback from record highs. The company cut list prices on Zepbound vials this week, pressuring margins and sending the stock lower. Zepbound and Mounjaro generated $10.1 billion in Q3 sales, making Lilly’s GLP-1 drugs the world’s top-selling franchise. Most analysts maintain Buy ratings, with 12-month targets around $1,060–$1,090.
6 December 2025
···
Eli Lilly (LLY) Stock Outlook: Can the Obesity-Drug Giant Keep Justifying a $1,000 Share Price?

Eli Lilly (LLY) Stock Outlook: Can the Obesity-Drug Giant Keep Justifying a $1,000 Share Price?

Eli Lilly shares traded above $1,000 on December 5, 2025, after recently crossing a $1 trillion market cap, the first for a healthcare company. The stock is up over 30% year to date despite an 8% pullback in the past week. Lilly is cutting prices on its obesity drug Zepbound and preparing to seek accelerated approval for a new weight-loss pill. The company’s dividend yield remains around 0.6%.
5 December 2025
··
Eli Lilly (LLY) Stock on December 2, 2025: Zepbound Price Cuts, GLP‑1 Boom and What Comes Next for the Trillion‑Dollar Drugmaker

Eli Lilly (LLY) Stock on December 2, 2025: Zepbound Price Cuts, GLP‑1 Boom and What Comes Next for the Trillion‑Dollar Drugmaker

Eli Lilly shares traded near $1,060 midday December 2, just below record highs, after a year of sharp gains fueled by obesity and diabetes drugs. The company cut U.S. self-pay prices for Zepbound on December 1, following a federal deal to lower GLP-1 prices. Lilly’s market cap briefly topped $1 trillion in November, the first for a healthcare firm. WHO issued its first guideline recommending GLP-1 drugs for obesity on December 1.
2 December 2025
··
Eli Lilly (LLY) Stock on December 1, 2025: Zepbound Price Cuts, $1 Trillion Milestone and 2026 Outlook

Eli Lilly (LLY) Stock on December 1, 2025: Zepbound Price Cuts, $1 Trillion Milestone and 2026 Outlook

Eli Lilly shares traded near $1,075 on December 1, 2025, giving the company a market cap of about $1.02 trillion, the first for a pharmaceutical firm. The company cut prices on its obesity drug Zepbound, lowering the starting dose to $299 per month from $349. Lilly’s GLP-1 drugs generated over $10 billion in Q3 revenue. The stock trades at over 70 times trailing earnings.
1 December 2025
··
1 … 7 8 9 10 11 12

Stock Market Today

  • NICE (TASE:NICE) Faces Valuation Question After 54% Share Decline
    May 23, 2026, 5:26 AM EDT. NICE, an AI-powered cloud platform company, has seen its share price fall 26% year to date and 54% over the past year despite reporting ₪3.0 billion in revenue and ₪529.6 million net income. The stock currently trades at ₪267.3, while analysts estimate a fair value of ₪620.96, suggesting the company may be undervalued amid strong AI-driven revenue growth and cloud adoption. However, risks include margin pressure from cloud investments and revenue churn from acquisitions. Investors are weighing near-term valuation concerns against NICE's long-term growth prospects in AI and customer engagement solutions.

Latest articles

XRP ETFs Hit $1.53 Billion as Bitwise Pulls Ahead, but the Chart Has a Catch

XRP Price Today: Weekend Drop Puts $1.30 on the Line as ETF Flows Defy Crypto Selloff

23 May 2026
NEW YORK, May 23, 2026, 05:20 EDT XRP fell to about $1.31 on Saturday, extending a weak week that has put the Ripple-linked token close to a near-term line traders have been watching. CoinMarketCap showed XRP down 3.9% over 24 hours, with trading volume of about $2.16 billion and market value near $81 billion. (CoinMarketCap) The move matters now because XRP is lagging even in a soft crypto tape. CoinGecko showed the token down 7.4% over seven days, compared with a 4.1% drop for the broader crypto market, leaving it ranked fifth by market value. (CoinGecko) This is a holiday-weekend
Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 23.05.2026

23 May 2026
LIVEMarkets rolling coverageStarted: May 23, 2026, 4:00 AM EDTUpdated: May 23, 2026, 5:37 AM EDT NICE (TASE:NICE) Faces Valuation Question After 54% Share Decline May 23, 2026, 5:26 AM EDT. NICE, an AI-powered cloud platform company, has seen its share price fall 26% year to date and 54% over the past year despite reporting ₪3.0 billion in revenue and ₪529.6 million net income. The stock currently trades at ₪267.3, while analysts estimate a fair value of ₪620.96, suggesting the company may be undervalued amid strong AI-driven revenue growth and cloud adoption. However, risks include margin pressure from cloud investments and
Go toTop